All In Biotech

Drug Trial Radar · NCT05996471

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion With rHuPH20, in Combination With CAB LA to Standard of Care in Virologically Suppressed Adults Living With HIV

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 185 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

185

Actual

Start

Aug 17, 2023

Primary completion

May 27, 2026

Study completion Nov 9, 2028

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Aug 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims at evaluating the efficacy of VH3810109, dosed in accordance with the dosing schedule as either intravenous (IV) infusion or subcutaneous (SC) infusion with recombinant hyaluronidase (rHuPH20), in combination with cabotegravir (CAB) intramuscular (IM) dosed in accordance with the dosing schedule in virologically suppressed, Antiretroviral therapy (ART)-experienced adult participants living with HIV. VH3810109 plus rHuPH20 plus Cabotegravir arm of the study has been discontinued based on preliminary results. The study will be conducted in 3 parts followed by a Long-Term Follow-up phase (LTFU).

Conditions

  • HIV Infections

Interventions

  • VH3810109Biological

    VH3810109 will be administered.

  • CabotegravirDrug

    Cabotegravir will be administered.

  • Standard of care (SOC)Drug

    Pre-baseline SOC antiretroviral therapy (ART) will be administered.

  • rHuPH20Biological

    rHuPH20 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 and Part 2B and 2C: Number of Participants with Plasma HIV-1 Ribonucleic acid (RNA) Greater Than or Equal to (≥)50 Copies per Millilitre (c/mL) per Snapshot Algorithm at Month 6Time frame: Month 6

Locations

45 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Palm Springs, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Fort Lauderdale, Florida

  • GSK Investigational Site

    Ft. Pierce, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Pensacola, Florida

  • GSK Investigational Site

    Sarasota, Florida

  • GSK Investigational Site

    Vero Beach, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Decatur, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Springfield, Massachusetts

  • GSK Investigational Site

    Southfield, Michigan

  • GSK Investigational Site

    Columbia, Missouri

  • GSK Investigational Site

    Newark, New Jersey

  • GSK Investigational Site

    Albuquerque, New Mexico

  • GSK Investigational Site

    Santa Fe, New Mexico

  • GSK Investigational Site

    Manhasset, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Greensboro, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Portland, Oregon

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    El Paso, Texas

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.